$39.86
Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
IDEAYA Biosciences Plans Phase 3 Trial for Lung Cancer Therapy
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
Overview
52-week range
$23
$43
86% of range
Avg surprise (last 3)
-5.5%
Avg reaction (last 2)
-6.8%
0% positive
Latest IV / EM
32%
EM ±5.0% · $40 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.22 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $-1.11 | $-1.07 | -3.7% | -35.4% | -0.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $1.33 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.88 | $-0.85 | -3.5% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.82 | $-0.75 | -9.3% | — | -13.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.60 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.68 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.53 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.46 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.50 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.49 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9M | $7M | — | $208M | — | — | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-122M | $-109M | — | $108M | $-89M | $-84M | — | $-67M |
| Net income | $-112M | $-99M | — | $119M | $-77M | $-72M | — | $-52M |
| EPS (diluted) | $-1.22 | $-1.11 | — | $1.33 | $-0.88 | $-0.82 | — | $-0.60 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $273M | $158M | $113M | $299M | $115M | $130M | $84M | $400M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $864M | $696M | $667M | $803M | $686M | $708M | $690M | $932M |
| Total assets | $1.31B | $1.03B | $1.11B | $1.19B | $1.04B | $1.10B | $1.12B | $1.24B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $111M | $93M | $86M | $93M | $82M | $77M | $65M | $59M |
| Total equity | $1.20B | $937M | $1.02B | $1.09B | $960M | $1.02B | $1.06B | $1.18B |